Table I.
Association of VASH2 staining with clinicopathological characteristics of breast cancer.
| Clinicopathologic characteristic | No. of patients | VASH2 staining | P-value | |
|---|---|---|---|---|
|
| ||||
| Low (%) | High (%) | |||
| Age | 0.344 | |||
| < 45 | 27 | 6 (22.3) | 21 (77.7) | |
| ≥45 | 72 | 23 (31.9) | 49 (68.1) | |
| Pathological stage | 0.299 | |||
| T1 | 50 | 17 (34.0) | 33 (66.0) | |
| T2–4 | 49 | 12 (24.5) | 37 (75.5) | |
| Tumor grade | <0.001 | |||
| G1–2 | 66 | 27 (40.9) | 39 (59.1) | |
| G3 | 33 | 2 (6.1) | 31 (93.9) | |
| Node status | 0.952 | |||
| Negative | 61 | 18 (29.5) | 43 (70.5) | |
| Positive | 38 | 11 (28.9) | 27 (71.1) | |
| ERα status | 0.066 | |||
| Negative | 34 | 6 (17.6) | 28 (82.4) | |
| Positive | 65 | 23 (35.4) | 42 (64.6) | |
| PR status | 0.734 | |||
| Negative | 47 | 13 (27.7) | 34 (72.3) | |
| Positive | 52 | 16 (30.8) | 36 (69.2) | |
| HER-2 status | 0.988 | |||
| Negative | 75 | 22 (29.3) | 53 (70.7) | |
| Positive | 24 | 7 (29.2) | 17 (70.8) | |
| Ki67 status | <0.001 | |||
| <14% | 28 | 19 (67.9) | 09 (32.1) | |
| ≥14% | 71 | 10 (14.1) | 61 (85.9) | |
| Total | 99 | 29 (29.3) | 70 (70.7) | |
VASH2, vasohibin-2; ER, estrogen receptor; HER, human epidermal growth factor receptor. VASH2 staining: Low, negative or weak staining; High, middle or strong staining.